Compare Deutsche Bank AG (DB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Novavax Inc — how do they compare? Deutsche Bank AG trades at $38.26 (market cap $72.15B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Deutsche Bank AG is far larger — about 55.5× Novavax Inc's market cap, and Deutsche Bank AG pays a 3.04% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| DB | NVAX | |
|---|---|---|
Market Cap | $72.15B | $1.30B |
Sector | Financials | Health |
52-Week High | $40.33 | $11.19 |
52-Week Low | $28.37 | $6.22 |
Dividend Yield | 3.04% | — |
Enterprise Value | — | $879.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $38.06, up 1.14% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with Q2 2026 revenue growth and a 10.02 P/E ratio trading below book value at 0.79. Recent developments include being named China's renminbi clearing bank and announcing a $500 million buyback. Net income margin improved to 22.04% in 2026, though Q2 earnings missed expectations.
DB presents a mixed investment case with attractive valuation metrics and strategic positioning in European banking, but faces execution risks from recent earnings miss and ongoing tax investigations. The stock trades at a discount to peers with moderate analyst support (21% buy rating) despite strong operational cash flow of $47.06 billion in 2025.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
